Evaluation of Remdesivir adverse drug reactions in cardiovascular disease patientes with COVID-19 admitted in Shahid Madani Hospital Tabriz

Abstract

Remdesivir is an antiviral prodrug, which was approved by the US Food and Drug Administration (FDA) for the treatment of patients with severe coronavirus disease 2019 (COVID-19). In December 2019, SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness in Wuhan, China. Clinical studies have reported COVID-19 itself can cause cardiovascular disease such as myocardial injury , arrhythmia , acute coronary syndrome and etc. Drug-disease interaction and side effects of drugs affecting patients with COVID-19 and concurrent cardiovascular disease are becoming a serious concern. Aim:A prospective cross-sectional study was carried out on admitted cardiovascular disease patients with COVID-19 that receiving Remdesivir were evaluated for occurring of Adverse Drug Reactions (ADRs) over a period of 12 months in Shahid Madani Hospital.Methods: In this study patients’ demographic information, clinical information about disease and family history, history of drug use, history of allergy, history of substance abuse and alcohol and smoking was recorded in the data collecting form. The results of these study were evaluated for probability of ADRs according to Naranjo standards to assess the possibility of complication and the prevalence of the complication. Results were evaluated in SPSS and patients’ clinical information was shown descriptively. For analytical analysis we used Logistic Regression test to assess the relation between the incidence of complications with the study factors, Multivariate Analysis using Linear Regression test was used to assess relation between study factors and ADRs incidence factors.Result: The sample size of this study was 152 patients ( median age, 65.85 ± 12.87 years; with majority of men [67.5%]) during this period. The average duration of receiving Remdesivir was 4.22 days.Conclusion:According to the data analysis with Naranjo Score , the study showed that Remdesivir related adverse drug reactions are possible.